Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma

Histopathology

Volumn 34, Issue 5, 1999, Pages 439-446

  McDonald, J W ^b   Pilgram, T K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

Author keywords

Bronchioloalveolar carcinoma; Immunohistochemistry

Indexed keywords

CYCLIN D1; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; CELL CYCLE; CELL NUCLEUS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

MARTES PENNANTI; NICOTIANA TABACUM;

EID: 0032982547     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00632.x     Document Type: Article

References (28)

1. 1. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54; 4855-4878.
2. 2. Gomyo Y, Ikeda M, Osaki M et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79; 2067-2072.
3. 3. Zhan Q. Bae I. Kastan MB, Fornace AF Jr. The p53-dependent gamma-ray response of GADD45. Cancer Res. 1994; 54; 2755-2760.
4. 4. Zhan Q, Fan S. Bae I et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9; 3743-3751.
5. 5. Fontanini G, Vignati S. Bigini D et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer 1995; 71; 1003-1007.
6. 6. Bodner SM, Minna JD, Jensen SM et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutations. Oncogene 1992; 7; 743-750.
7. 7. Iggo R, Gatter K, Bartek J et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335; 675-679.
8. 8. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73; 1059-1065.
9. 9. Fracchiolla NS, Pruneri G, Pignataro L et al. Molecular and immunohistochemical Analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas. Cancer 1997; 79; 1114-1121.
10. 10. Chen X, Bargonetti J. Prives C, p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 1995; 55; 4257-4263.
11. 11. Mate JL, Ariza A, Aracil A et al. Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J. Pathol. 1996; 180; 395-599.
12. 12. Marchetti A, Doglioni C, Barbareschi M et al. p21 RNA and protein expression in non-small-cell carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12; 1319-1324.
13. 13. Liebow AA. Bronchioloalveolar carcinoma. Adv. Intern. Med. 1960; 10; 329-358.
14. 14. Hsu C-P, Chen C-Y, Hsu N-Y. Bronchioloalveolar carcinoma. J. Thorac. Cardiovasc. Surg. 1995; 110; 374-381.
15. 15. Saldana MJ, Mones JM. Adenocarcinoma. In Saldana MJ ed. Pathology of Pulmonary Disease. Philadelphia: Lippincott, 1994; 535-540.
16. 16. Nuorva K, Soini Y, Kamel D et al. p53 protein accumulation and the presence of human papillomavirus DNA in bronchioloalveolar carcinoma correlate with poor prognosis. Int. J. Cancer 1995; 64; 424-429.
17. 17. Kitamura H, Kameda Y, Nakamura N et al. Atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am. J. Surg. Pathol. 1996; 20; 553-562.
18. 18. Bongiorno PF, Whyte RI, Lesser EJ et al. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J. Thorac. Cardiovasc. Surg. 1994; 107; 590-595.
19. 19. Konishi T, Lin Z, Fujino S, Kato H, Mori A. Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Hum. Pathol. 1997; 28; 544-548.
20. 20. Saldana MJ, Sridhar KS, Thurer RJ. Classification, staging, and etiology of lung cancer. In Saldana MJ ed. Pathology of Pulmonary Disease. Philadelphia: Lippincott, 1994; 523-530.
21. 21. Beahrs OH, Henson DR, Hutter RVP et al. (eds). American Joint Committee on Cancer Manual for Staging of Cancer, 4th edn. Philadelphia: Lippincott, 1992.
22. 22. Warnke R, Levy R. Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J. Histiochem. Cytochem. 1980; 28; 771-776.
23. 23. Betticher DC, Heighway J, Hasleton PS et al. Prognostic significance of CCND1 (Cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br. J. Cancer 1996; 73; 294-300.
24. 24. Sheyn I. Noffsinger AE, Heffelfinger S et al. Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas. Hum. Pathol. 1997; 28; 270-276.
25. 25. Nakagawa H, Zukerberg L, Togawa K et al. Human cyclin D1 oncogene and esophageal squamous cell carcinoma. Cancer 1995; 76; 541-549.
26. 26. Lukas J, Bartkova J, Welcker M et al. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 1995; 10; 2125-2134.
27. 27. Xu J. Gimenez-Conti IB, Cunningham JE et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 1998; 83; 204-212.
28. 28. Pignataro L, Capaccio P, Carboni N et al. p53 and cyclin D1 expression in carcinomas of the parotid gland. Anticancer Res. 1998; 18 (2B); 1287-1290.